| Document |
Document Title |
|
WO/2015/197309A1 |
The present invention is related to a novel and improved process for the manufacture of compounds of formula (I) or salts thereof herein designated as benzylsulfonyl-Ser-X-4-amidinobenzylamide, wherein R is a C1 to C6 linear or branched ...
|
|
WO/2015/200322A1 |
In certain embodiments, the invention relates to methods for treating migraine (e.g. episodic migraine, chronic migraine, retinal migraine, ophthalmoplegic migraine, acephalgic migraine, migrainous disorder, menstrual migraine, abdominal...
|
|
WO/2015/200656A1 |
A short chain polypeptide having antioxidant activity is provided. The short chain polypeptide has 2 to 4 amino acids bonded to form a polypeptide chain having an amine- terminal end and a carboxyl terminal end; wherein a net charge of t...
|
|
WO/2015/200305A1 |
The present disclosure relates to methods for making asunaprevir, useful treatment of Hepatitis C virus (HCV) infection, and its intermediates.
|
|
WO/2015/194205A1 |
Disclosed is a cyclic dipeptide-containing composition comprising specific amounts of: tyrosine-containing cyclic dipeptides selected from the group consisting of cyclotryptophanyltyrosine, cycloseryltyrosine, cycloprolyltyrosine, cyclot...
|
|
WO/2015/194035A1 |
Disclosed is a cyclic dipeptide-containing composition comprising specific amounts of: tyrosine-containing cyclic dipeptides selected from the group consisting of cyclotryptophanyltyrosine, cycloseryltyrosine, cycloprolyltyrosine, cyclot...
|
|
WO/2015/189791A1 |
Disclosed herein are novel compounds of formula (I) as described herein, and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) com...
|
|
WO/2015/192052A1 |
Disclosed herein are compounds having activity as EGFR inhibitors. In some examples, the compounds can comprise an EGFR binding moiety; a linker; and a detectable moiety, therapeutic moiety, or a combination thereof. Also provided herein...
|
|
WO/2015/187540A1 |
Peptide-drug conjugates comprising p-aminobenzyl carbamoyl or p-aminobenzolyl carbonate self-immolating linkers are disclosed. The peptide-drug conjugates comprise a peptide moiety that can be cleaved by cellular proteases, bound to the ...
|
|
WO/2015/181688A1 |
The peptides have the general following formula: X–Pro*–Pro*–Xaa–Y in which: •Xaa is selected from Leucine (Leu, L), Arginine(Arg, R), Lysine (Lys, K), Alanine (Ala, A), Serine (Ser, S), and Aspartic acid (Asp, D); •At the N ...
|
|
WO/2015/183985A2 |
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of naphthoquinones, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutica...
|
|
WO/2015/183984A2 |
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of tocopherol, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically a...
|
|
WO/2015/183963A2 |
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of redox-active parabenzoquinones (RPBQs), and/or naturally or artificially occurring derivatives, anal...
|
|
WO/2015/183995A2 |
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues...
|
|
WO/2015/183978A1 |
Provided are peptide analogs, pharmaceutical compositions comprising such compounds, and methods of treating cancer with such compounds.
|
|
WO/2015/174500A1 |
[Problem] To provide a thickening composition that does not lose viscosity even in the presence of organic acids such as ascorbic acid and salts thereof. [Solution] A thickening composition containing a polyhydric alcohol, water, and org...
|
|
WO/2015/173802A1 |
The present invention is directed to a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C'-terminus of PAR-1, or an active variant the...
|
|
WO/2015/158306A1 |
Provided are a glyoxalase I irreversible inhibitor as represented by the formula I, a preparation method therefor, and uses thereof. In the present invention, an irreversible inhibitor reacts with glyoxalase I in a covalent bond mode so ...
|
|
WO/2015/155976A1 |
As an anti-tumor drug having an excellent anti-tumor effect and excellent safety and also having an excellent therapeutic effect, an antibody-drug conjugate is provided, said conjugate being characterized by being produced by linking an ...
|
|
WO/2014/134562A9 |
The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ame...
|
|
WO/2015/154029A1 |
The present invention provides a family of novel cytotoxic pentapeptides. These compounds show potent antitumor activities against several cancer lines. The antibody-drug conjugates prepared from those pentapeptides can efficiently kill ...
|
|
WO/2015/149607A1 |
Disclosed are a tripeptide epoxyketone compound, a preparation method thereof, and a use thereof in the preparation of anti-tumour drugs.
|
|
WO/2015/148923A1 |
The invention provides cell therapy compositions and associated methods. In particular embodiments, improved therapeutic cells and improved cell-based gene therapies for promoting cell or tissue formation, regeneration, repair or mainten...
|
|
WO/2015/140807A1 |
A reverse-osmosis membrane filter comprising: a porous support layer; a porous skin layer, and at least one water binding composition predominantly bound between the skin layer and the support layer.
|
|
WO/2015/140481A1 |
Antimicrobial compound, as well as the salts, derivatives and analogues thereof, said compound being represented by the general formula (I): where R1 is a peptide part P1 or a peptide part P2.
|
|
WO/2015/137846A1 |
This invention relates to the field of medicine and concerns a method for the prophylaxis or treatment of diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, which envisages the use of an effective amount of a c...
|
|
WO/2015/138819A1 |
In some embodiments, a chemical composition may include C60, serrapeptase, or a tetrapeptide. The tetrapeptide may include ALA, GLU, ASP, GLY. In some embodiments, the chemical composition may include a dipeptide. The dipeptide may inclu...
|
|
WO/2015/131355A1 |
A compound of formula I is an intermediate in a method for preparing a natural product histone deacetylase inhibitor Thailandepsin B. The method comprises the following steps: 1) adding an elemental iodine into a mixed solvent of dichlor...
|
|
WO/2015/123783A1 |
Compounds that are cathepsin B substrates and that are useful as imaging probes, for example in positron emission tomography (PET) or fluorescence imaging are described.
|
|
WO/2015/124540A1 |
The invention provides a blood brain barrier shuttle comprising a brain effector entity and a brain targeting peptide.
|
|
WO/2015/126269A1 |
The invention relates to a method of synthesis of a biopolymer derivative, preferably a chitosan derivative, comprising the formation of a peptide bond. The invention also relates to the biopolymer derivative, and use of the biopolymer d...
|
|
WO/2015/121769A1 |
The present invention provides a process for the preparation of methyl N- [(benzyloxy)carbonyl]-L-leucyl-L-phenylalaninate of Formula (II), which can be used as an intermediate for the preparation of carfilzomib.
|
|
WO/2015/117196A1 |
The invention concerns agents with antibacterial activity, their production and use in the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin- type antibiotics, of structure X-W-L-V, whe...
|
|
WO/2015/118546A1 |
Mucolytic compositions comprising short peptides are provided, and methods for promoting mucus clearance and treating diseases or disorders where mucus is accumulated or disturbing breathing.
|
|
WO/2015/113481A1 |
Disclosed are oligopeptide molecules, preparation methods therefor and uses thereof. Said oligopeptides comprise CD1、CD2、CD3、CD4、CD5、CD6、CD7、CD8、CD9、CD10
CD11、CD12、CD13 and CD14. The amino acid sequences are show...
|
|
WO/2015/116806A1 |
Provided are pro-substrates useful in assays of living cells. The pro-substrates can be used to detect the presence or absence of enzymes, such as luciferase, in living cells. The pro-substrates can be coelenterazine derivatives or analo...
|
|
WO/2015/113760A1 |
The present invention provides one or more compounds of formula (I) for conjugation to small molecules, polymers, peptides, proteins, antibodies, antibody fragments etc.
|
|
WO/2015/107170A1 |
The present invention relates to the field of molecular biochemistry and medicine, and in particular to ligands comprising modified amino acid residues, targeting the amyloid-β peptide associated with Alzheimer's disease for prevention ...
|
|
WO/2015/096725A1 |
Provided are a linear lipopeptide with an end group having a lipophilic structure, a preparation method for the lipopeptide, and a use thereof in preparing an anti-radiation injury medicament. The lipopeptide is one lipophilic structural...
|
|
WO/2015/100145A1 |
The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic...
|
|
WO/2015/100144A1 |
Crystalline forms of the anti-HCV compound (1R,5S,8S,9S,10R,22aR )-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcy
clopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difl
uoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,...
|
|
WO/2015/094111A1 |
The embodiments relate to surface-binding peptides having the capability of binding to surfaces of biocompatible materials and can thereby be used to immobilize various heterologous molecules of interest onto the surface. This means that...
|
|
WO/2015/083816A1 |
Provided is a new NK3 receptor selective ligand which is expected to have high activity and high selectivity, and to act in a sustained manner in vivo. A compound expressed by formula (I) X1 - A2 - A3 - X4 - X5 - Met - NH2 [the symbols...
|
|
WO/2015/080671A1 |
The present invention relates to the use of peptides, peptoids and/or peptidomimetics capable of self-assembling and forming a (nanofibrous) hydrogel in biofabrication. The present invention further relates to methods for preparing hydro...
|
|
WO/2015/077763A1 |
The present invention provides a novel class of medicament based on CXCR antagonistic peptides. Among other things, the present invention provides peptides, compositions and methods for treating diseases, disorders and conditions in whic...
|
|
WO/2015/067450A1 |
The invention relates to a method for producing amines, comprising the following steps: a. reacting a (i) carboxylic acid amide of general formula (I) or (ii) carboxylic acid diamide of general formula (II) or (iii) di-, tri-, or polypep...
|
|
WO/2015/069876A1 |
IDE-binding probes and assays for the identification of IDE-binding and IDE- inhibiting compounds are provided. Pharmaceutical compositions of macrocyclic IDE inhibitors are also provided, including compositions in which such IDE inhibit...
|
|
WO/2015/067708A1 |
Disclosed are two crystalline forms of S-acetyl glutathione (SAG) called Form A and Form B, obtained by crystallisation of SAG from mixtures of water-acetone, water-ethanol or water-methanol, preferably acetone, under controlled conditio...
|
|
WO/2015/067493A1 |
The invention relates to Lysyl-Prolyl- Threonine lyophilized formulations, in particular to L-Lysyl-D-Prolyl-L-Threonine lyophilized formulations, that are stable in storage, and to a process for preparing the lyophilized formulations. M...
|
|
WO/2015/063326A1 |
The present invention relates to peptidyl phosphonate esters compounds and their use selective inhibitors of proteinase 3, in particular for treating or diagnosing inflammator autoimmune and cancer disorders. More specifically, the inven...
|
